You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Moodys
AstraZeneca
Johnson and Johnson
Colorcon

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

WELLCOVORIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Wellcovorin patents expire, and when can generic versions of Wellcovorin launch?

Wellcovorin is a drug marketed by Glaxosmithkline and is included in five NDAs.

The generic ingredient in WELLCOVORIN is leucovorin calcium. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the leucovorin calcium profile page.

US ANDA Litigation and Generic Entry Outlook for Wellcovorin

A generic version of WELLCOVORIN was approved as leucovorin calcium by WEST-WARD PHARMS INT on September 14th, 1987.

  Start Trial

Summary for WELLCOVORIN
Drug patent expirations by year for WELLCOVORIN
Recent Clinical Trials for WELLCOVORIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Southwest Oncology GroupPhase 2
ECOG-ACRIN Cancer Research GroupPhase 3
National Cancer Institute (NCI)Phase 2/Phase 3

See all WELLCOVORIN clinical trials

US Patents and Regulatory Information for WELLCOVORIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline WELLCOVORIN leucovorin calcium INJECTABLE;INJECTION 087439-001 Oct 19, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline WELLCOVORIN leucovorin calcium INJECTABLE;INJECTION 089834-001 Jan 23, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline WELLCOVORIN leucovorin calcium INJECTABLE;INJECTION 089833-001 Jan 23, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline WELLCOVORIN leucovorin calcium INJECTABLE;INJECTION 089465-001 Jan 23, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline WELLCOVORIN leucovorin calcium TABLET;ORAL 018342-002 Jul 8, 1983 DISCN Yes No   Start Trial   Start Trial   Start Trial
Glaxosmithkline WELLCOVORIN leucovorin calcium TABLET;ORAL 018342-001 Jul 8, 1983 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
Merck
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.